Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML SOUTH SAN FRANCISCO, Calif., May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals,...